Skip to main content
. 2017 Sep 18;8(50):87607–87622. doi: 10.18632/oncotarget.20999

Figure 3. Necdin null leukemia cells expressing MLL-AF9 are sensitive to chemotherapy treatment.

Figure 3

(A) and (B) WT and Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations of chemotherapy drug cytarabine (AraC). 24 (A) and 48 (B) hours after AraC treatment, the viability of treated leukemia cells was measured by cell counting (*p<0.05, **p<0.01, n=3). (C) WT and Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations of AraC. 24 hours after AraC treatment, the frequency of total apoptotic cells (Annexin V+) was determined by flow cytometry analysis (*p<0.05, n=3). (D) and (E) WT and Necdin null leukemia cells expressing MLL-AF9 were treated with DMSO or different concentrations of AraC. 48 hours after AraC treatment, the frequency of early apoptotic cells (Annexin V+PI−) and late apoptotic cells (Annexin V+PI+) was determined by flow cytometry analysis (***p<0.001, n=3). (F) Wild type and Necdin null leukemia cells were treated with DMSO or AraC (0.2 μM). 24 hours later, cell cycle status of leukemia cells was determined by flow cytometry analysis (*p<0.05, ***p<0.001, n=3). (G) Wild type and Necdin null leukemia cells were treated with DMSO or AraC. 6 hours later, the expression of Bcl2, Bax, and p53 in leukemia cells was determined by quantitative real-time PCR analysis (**p<0.01, ***p<0.001, n=3).